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Imidazolylpropylguanidines derived from impromidine and arpromidine are more potent and
efficacious agonists at the guinea pig histamine H2 receptor (gpH2R) than at the human H2R
(hH2R) in the GTPase assay. Additionally, such guanidines are histamine H1 receptor (H1R) ant-
agonists with preference for the human relative to the guinea pig receptor. The purpose of this
study was to examine structure-activity relationships of guanidines at human and guinea pig
H1R and H2R species isoforms expressed in Sf9 insect cells. Three impromidine analogues and six
arpromidine analogues exhibited agonistic activity at H2R and antagonistic activity at H1R as
assessed in the steady-state GTPase assay. Species selectivity of derivatives was similar as compa-
red with the parent compounds. None of the structural modifications examined (different aro-
matic ring systems and different ring substituents) was superior in terms of H2R potency and
efficacy relative to impromidine and arpromidine, respectively. These data point to substantial
structural constraints at the agonist binding site of H2R. Guanidines exhibited distinct struc-
ture-activity relationships for H1R antagonism in a radioligand competition binding assay and
the GTPase assay and for H1R inverse agonism. Our data indicate that it is difficult to obtain gua-
nidine-type agonists with high potency and high efficacy for hH2R, but those compounds may be
useful tools for exploring the antagonist binding site and constitutive activity of H1R.
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Introduction
Histamine (HA, 1) exerts its biological effects through
four receptor subtypes, designated as H1, H2, H3, and H4
receptors (H1R, H2R, H3R, H4R), respectively [1–3]. The H1R
couples to Gq-proteins, the H2R couples to Gs-proteins,
and the H3R and H4R couple to Gi/Go-proteins. We are par-
ticularly interested in the development of H2R agonists
that could be used for the treatment of acute heart fail-
ure, acute promyelocytic leukemia, and inflammatory
diseases [4, 5]. H2R agonists are divided into two classes.
The first class comprises small molecules related to HA 1
(Fig. 1) such as amthamine and dimaprit. The amino
group of HA forms an ionic interaction with Asp-98 in
transmembrane domain 3, and the imidazole ring inter-
acts with Tyr-182 and Asp-186 in transmembrane domain
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5 [6, 7]. The second class of H2R agonists consists of long-
chained and more bulky molecules, impromidine (IMP,
2) and arpromidine (ARP, 6) (Fig. 1) being the prototypes
[4, 8]. Highest potency is found for compounds with a
three-membered instead of a two-membered carbon
chain as in histamine connecting the imidazole ring and
the basic group. The corresponding partial structures of
impromidine and histamine are considered as function-
ally equivalent groups that are important for the recep-
tor activation i.e., the guanidino group and the imidazo-
lylpropyl moieties of IMP and ARP are supposed to form
similar interactions with the H2R as the amino group and
imidazole groups of HA, respectively [5, 9]. Additionally,
the 2-(5-methylimidazol-4-ylmethylthio)ethyl moiety of
IMP and the 3-(4-fluorophenyl)-3-(2-pyridyl)propyl substi-
tuent of ARP interact with a pocket formed by multiple
residues in transmembrane domains 3, 6, and 7 [9]. Tradi-
tionally, measurement of positive chronotropic effects in
the guinea pig right atrium has been used as a read-out
for the measurement of H2R agonist potency and efficacy
[1, 2, 4]. However, recent studies have revealed substan-
tial pharmacological differences between hH2R and
gpH2R recombinantly expressed in Sf9 insect cells [9, 10].
Specifically, at gpH2R, IMP and ARP are full agonists and
up to 30-fold more potent than HA. In contrast, at hH2R,
IMP and ARP are only partial agonists and just sixfold
more potent than HA [9, 10]. Modeling and mutagenesis
studies showed that the pharmacological differences
between hH2R and gpH2R are due to the non-conserved
Asp-271 in transmembrane domain 7 of gpH2R (Ala-271
in hH2R) and Tyr-17 in transmembrane domain 1 of
gpH2R (Cys-17 in hH2R). In addition, IMP and ARP-derived
compounds are H1R antagonists with preference for
gpH1R relative to hH1R, Asn-84 in transmembrane
domain 2 playing a crucial role in conferring species-
selectivity to H1R ligands [11, 12].
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Figure 1. Structures of histamine 1, amthamine, dimaprit, and
the highly potent guanidine-type H2R agonists impromidine 2
and arpromidine 6.
Scheme 1. Synthetic pathways to the investigated guanidine-
type histamine H2 receptor agonists 2–12.
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Our long-term goal is to obtain highly potent and effi-
cacious hH2R agonists. The purpose of this study was to
extend the structure-activity relationships for IMP-
derived guanidines 2–5 and ARP-derived guanidines 6–
12 (Scheme 1) for agonistic activity at hH2R and gpH2R
and antagonistic activity at hH1R and gpH1R. In case of
H2R, fusion proteins of the receptor and short splice var-
iant of Gsa protein (hH2R-GsaS and gpH2R-GsaS) were used to
determine agonist-stimulated high-affinity GTP hydroly-
sis with high sensitivity [9,10]. In case of H1R, we meas-
ured GTPase activity of the receptor coupled to insect cell
Gq-proteins, enhancing the signal with regulator of G-
protein signaling (RGS) proteins [11, 13].
Results and discussion
Chemistry
The guanidine-type histamine H2R agonists were accessi-
ble according to the synthetic pathways outlined in
Scheme 1 following the procedures described for 2–10
[14–17]. The guanidines 11 and 12 [18] were synthesized
via the corresponding Boc-protected guanidines by step-
wise aminolysis of tert-butyl diphenoxymethylidenecar-
bamate as reported for structurally related alkyl guani-
dine-N-carboxylates [19], followed by deprotection with
hydrochloric acid. The pertinent phenyl(thiazol-2-yl)pro-
pylamines were prepared from the corresponding phe-
nyl(thiazol-2-yl)ketones in analogy to a previously
describedmethod [20].
Pharmacology
Analysis of the interaction of histamine and guanidines 2-
12 with hH2R-GsaS and gpH2R-GsaS
HA activated the GTPase activity of hH2R-GsaS and gpH2R-
GsaS with similar potency and was a full agonist (Table 1).
IMP 2 activated hH2R-GsaS with a l sixfold higher potency
than HA and was a strong partial agonist. Substitution of
the methylimidazolyl moiety of IMP 2 by thiophene 3
slightly reduced efficacy but not potency. The introduc-
tion of a phenyl ring 4 reduced the potency and efficacy,
whereas a pyridyl ring 5 reduced only potency. At gpH2R-
GsaS, IMP and its derivatives 2–5were all more potent and
efficacious than at hH2R-GsaS. The various ring substitu-
tions had no effect on efficacy but similar to hH2R-GsaS,
introduction of a phenyl ring 4 or pyridyl ring 5 reduced
potency.
At hH2R-GsaS, ARP, bearing a 4-fluorophenyl group 6,
was similarly potent and efficacious as IMP 2. Extension
of the chain length in 6, resulting in the higher homolo-
gue 7, reduced both potency and efficacy. Substitution of
the pyridyl ring against phenyl 8 slightly increased effi-
cacy but reduced potency. Substitution of the additional
phenyl ring with 4-fluoro (8ﬁ 9) slightly reduced the effi-
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Table 1. Agonist potencies and efficacies of HA and guanidines at hH2R-GsaS and gpH2R-GsaS in the GTPase assay.
hH2R-GsaS gpH2R-GsaS EC50 hH2R-GsaS/
EC50 gpH2R-GsaS
Compd. Efficacy EC50 (nM) Rel. pot. Efficacy EC50 (nM) Rel. pot.
1 1.00 1,200 l 300 100 1.00 1,200 l 200 100 1.00
2 0.82 l 0.04a) 210 l 20a) 570 0.99 l 0.09 42 l 10 2,900 5.00
3 0.74 l 0.06a) 230 l 20a) 520 1.00 l 0.01 51 l 12 2,400 4.51
4 0.77 l 0.14a) 420 l 57a) 290 0.97 l 0.01 120 l 16 1,000 3.50
5 0.83 l 0.05a) 510 l 23a) 240 0.92 l 0.03 170 l 15 710 2.96
6 0.80 l 0.05a) 180 l 50a) 670 1.00 l 0.06 65 l 8 1,800 2.77
7 0.58 l 0.02a) 600 l 25a) 200 0.85 l 0.09 170 l 23 710 3.53
8 0.90 l 0.13 470 l 83a) 260 1.03 l 0.08 120 l 27 1,000 4.01
9 0.84 l 0.05a) 360 l 15a) 330 1.03 l 0.10 83 l 1 1,500 4.30
10 0.71 l 0.02a) 710 l 100a) 170 0.98 l 0.01 240 l 6 500 2.95
11 0.51 l 0.14a) 810 l 130a) 150 0.87 l 0.09 210 l 9 570 3.86
12 0.50 l 0.11a) 790 l 110a) 150 0.84 l 0.04 200 l 15 600 3.95
Steady-state GTPase activity in Sf9 membranes expressing hH2R-GsaS and gpH2R-GsaS was determined as described in Experimental
(section 3). Reaction mixtures contained ligands at concentrations from 1 nM to 100 lM as appropriate to generate saturated con-
centration/response curves. Data were analyzed by non-linear regression and were best fit to sigmoid concentration/response
curves. Typical basal GTPase activities ranged between l1–2 pmol/mg/min, and the maximum stimulatory effect of histamine
(100 lM) amounted to 250–350% above basal. The efficacy (Emax) of histamine was determined by non-linear regression and was set
1.00. The Emax values of other agonists were referred to this value. Data shown are the means l SD of 5–8 experiments performed in
duplicates each.
a) p a 0.05 for comparison of hH2R-GsaS and gpH2R-GsaS. The relative potency (rel. pot.) of histamine was set 100, and the potencies of
other agonists were referred to this value.
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cacy with a small effect on potency. Substitution of the 4-
fluorophenyl group of ARP 6 with 3,4-dichlorophenyl 10
had a negative impact in terms of potency and efficacy.
Among ARP derivatives substituted with a thiazole ring
11, 12, 3,4,5-trichloro- and 4,5-dichloro substitutions
were unfavorable in terms of agonist potency and effi-
cacy.
At gpH2R-GsaS, ARP 6was slightly less potent than IMP 2
but similarly efficacious. Potencies and efficacies of ARP-
derived guanidines 7–12 were higher at gpH2R-GsaS than
at hH2R-GsaS. The substitutions in 7, 11, and 12 that exhib-
ited a negative impact on efficacy at hH2R-GsaS also had a
negative impact on efficacy at gpH2R-GsaS. Similarly to the
observations made for hH2R-GsaS, ARP-derived guanidines
7–12were less potent than the parent compound 6.
Analysis of the effects of histamine and guanidines at
hH1R and gpH1R
The interaction of ligands with H1R was examined in a
radioligand competition assay, using the antagonist
[3H]mepyramine as probe. Guanidine 6 (ARP) exhibited
the highest affinity for hH1R among all compounds
examined (Table 2). The affinity of ARP for hH1R sur-
passed the affinity of HA by almost sixfold. Among ARP
derivatives, extension of the connecting chain in 6 by
one methylene group 7 had the most pronounced nega-
tive impact on affinity. IMP and its analogue 3 showed up
to fivefold lower affinity for hH1R than HA.
The affinities of all ligands studied were significantly
different at hH1R and gpH1R. HA exhibited a lower affi-
nity for gpH1R than for hH1R, whereas the opposite was
true for guanidines 2, 3, 6, 7, 9, and 10. Among the com-
pounds studied, ARP showed the highest affinity for
gpH1R, being 150-fold more potent than HA. All substitu-
tions examined in guanidines (2 versus 3 and 6 versus 7, 9,
and 10) reduced affinity for gpH1R. Like ARP 6, guani-
dine 9 exhibited substantial selectivity for gpH1R rela-
tive to hH1R, whereas species-selectivity for 3 and 7 was
just twofold.
In a recent study, we showed that NG-acylated imidazo-
lylpropylguanidines are potent hH2R- and gpH2R agonists
and partial hH1R agonists [10]. These data prompted us to
address the question whether IMP- and ARP-derived gua-
nidines exhibit agonistic effects at hH1R as well. How-
ever, agonistic activity of guanidines at hH1R was only
minimal for compound 3 and virtually absent for 4 and
11 (Table 3). Intriguingly, for 6, 7, and 9, inverse agonistic
activity was detected as reflected by a decrease of basal
GTPase activity. At gpH1R, 3 lacked agonistic activity, but
similarly to the data obtained with hH1R, 6, 7, and 9
showed inverse agonistic activity at gpH1R. Compound 9
reduced basal GTP hydrolysis in membranes expressing
gpH1R with an IC50 value of 84 l 12 nM (n = 3). This value
is consistent with the KB value determined in functional
competition experiments of 9 with HA (see below). More-
over, the neutral antagonist 3 (10 lM) shifted the IC50 of 9
to 1.5 l 0.2 lM (n = 3). Collectively, our data corroborate
the notion that hH1R exhibits constitutive, i. e. agonist-
independent, activity and that several guanidines are
inverse H1R agonists [11].
Finally, we also examined the antagonistic effects of
guanidines in a functional assay, determining inhibition
of HA-stimulated high-affinity GTP hydrolysis (Table 3).
Similar to the data obtained in the radioligand competi-
tion assay, ARP 6 exhibited the highest affinity for hH1R
among all guanidines studied. Except for the higher
homologue 7, ARP derivatives exhibited lower antagonis-
tic potency at hH1R than the parent compound. The IMP
derivatives 3 and 4 showed low antagonistic affinity for
hH1R as well. With respect to gpH1R, ARP 6 was the most
potent antagonist as well. The structural variations in 7
and 9 had little impact on antagonist potency, but substi-
tution of the phenyl ring with chlorine 10, 11 had a nega-
tive impact on antagonist affinity. IMP derivatives 3 and
4 exhibited about 10-fold lower antagonistic potency
than ARP at gpH1R.
H2R agonists are interesting potential drugs for the
treatment of various human disorders including acute
heart failure, acute promyelocytic leukemia and inflam-
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Table 2. Affinities of HA and guanidines at hH1R and gpH1R in
the [3H]mepyramine competition binding assay.
hH1R gpH1R Ki hH1R/
Ki gpH1R
Compd. Ki
(lM)
Rel.
affinity
Ki
(lM)
Rel.
affinity
1 (HA) 2.0 l 0.19a) 100 4.6 l 0.24 100 0.43
2 6.0 l 1.3a) 33 0.92 l 0.14 500 6.53
3 9.1 l 0.4a) 22 4.0 l 1.1 120 2.23
6 0.34 l 0.08a) 590 0.03 l 0.01 15,000 11.3
7 2.6 l 0.1a) 77 1.2 l 0.1 380 2.17
9 1.2 l 0.1a) 170 0.11 l 0.01 4,200 10.9
10 6.6 l 0.2a) 330 1.5 l 0.03 310 4.40
[3H]Mepyramine competition binding in Sf9 membranes expres-
sing hH1R or gpH1R with RGS4 or RGS19 was determined as
described in Experimental (section 3). Reaction mixtures con-
tained Sf9 membranes (20–25 lg of protein), 2 nM [3H]mepyra-
mine and unlabeled guanidines at concentrations of 10 nM to
1 mM as appropriate to generate saturated competition curves.
Data were analyzed by non-linear regression and were best fit
to one-site (monophasic) competition curves. Data shown are
the means l SD of 3–5 experiments performed in duplicate.
The relative affinity (rel. affinity) of HA was set 100, and the affi-
nities of other ligands were referred to this value.
a) p a 0.05 for comparison of hH1R and gpH1R.
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matory diseases [4, 5]. In order to come closer to these
ambitious goals, it is necessary to develop highly potent
and efficacious hH2R agonists. While initial studies with
the guinea pig atrium showed that the guanidines IMP 2
and particularly ARP 6 are highly potent H2R agonists
[4, 8], subsequent studies with human cell systems were
rather disappointing since IMP and ARP showed reduced
efficacy and potency compared to the guinea pig atrium
[21, 22]. The unfavorable pharmacological properties of
the available H2R agonists in human systems substan-
tially delayed the further development of agonists, parti-
cularly because the molecular basis for the apparent
pharmacological difference between hH2R and gpH2R
remained elusive. Finally, with a lag period of almost a
decade, it became clear that two defined amino acid dif-
ferences in transmembrane domains 1 and 7 between
hH2R and gpH2R account for the pharmacological differ-
ences [9]. These advances rekindled interest in the devel-
opment of H2R agonists [5, 10].
ARP, bearing a 4-fluorophenyl group at the guanidino
group, is one of the most potent hH2R agonists known so
far, but it is still only a partial agonist and less potent
than at gpH2R (Table 1) [9]. Since substitution of 4-fluoro-
phenyl by 4-chloro and 4-bromo slightly enhanced
potency [9], we explored several halogen ring substitu-
tions in our present study. Unfortunately, variousmodifi-
cations including introduction of a second 4-fluorophe-
nyl group 9 and introduction of a 3,4-dichloro- or a 3,4,5-
trichlorophenyl group 10–12 had negative rather than
positive effects on agonist potency and efficacy at hH2R.
However, this result was not completely unexpected
since a 3,4-difluoro substitution also slightly reduced
agonist potency at hH2R [9]. Other modifications such as
substitution of pyridyl by phenyl 6, 8 increased efficacy,
but only at the expense of potency. The newly introduced
modifications 8–12 in ARP did not enhance potency and
efficacy at gpH2R either. At gpH2R, ARP derivatives stud-
ied weremore potent and efficacious than at hH2R, point-
ing to a systematic difference in interaction of agonists
with the receptor in the two species. Only with respect to
efficacy of 8, there was no statistically significant differ-
ence between hH2R and gpH2R and no compound showed
preference for hH2R relative to gpH2R.
The situation regarding structural modifications using
IMP as starting point was similar to what we observed for
the ARP series. Specifically ring substitutions in IMP
(thiophene, phenyl, and pyridyl) 3–5 were not advanta-
geous with respect to potency at hH2R and gpH2R. Addi-
tionally, the ring substitutions did not increase but
rather tended to decrease agonist efficacy at hH2R and
gpH2R. Although, on first glance, these results may seem
disappointing, the data are actually very helpful for
future ligand design. Specifically, our results clearly
point to substantial structural constraints in the agonist-
binding site both in hH2R and gpH2R. As a consequence of
our data, it is probably not a promising strategy to
further introduce gradual structural changes in the aro-
matic ring substituents of guanidines in order to obtain
highly potent and efficacious hH2R agonists. Rather,
future studies should examine more drastic structural
changes such as the introduction of saturated ring sys-
tems. Based on the present data, it is evident that the
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Table 3. Antagonist potencies and agonist/inverse agonist efficacies of guanidines at hH1R and gpH1R in the GTPase assay
hH1R gpH1R KB hH1R/
KB gpH1R
Compd. KB (nM) Efficacy KB (nM) Efficacy
3 BU-E-23 4,000 l 500a) 0.07 l 0.04 400 l 180 0.00 l 0.03 10.0
4 BU-E-14 2,600 l 210a) 0.04 l 0.02 560 l 180 0.04 l 0.03 4.64
6 ARP 320 l 80a) –0.11 l 0.05 49 l 13 –0.12 l 0.06 6.53
7 BU-E-84 370 l 120a) –0.16 l 0.07 53 l 4 –0.18 l 0.04 6.98
9 FrA 19 660 l 48a) –0.15 l 0.02 72 l 3 –0.17 l 0.06 9.12
10 BU-E-82 1,300 l 310a) –0.04 l 0.02 890 l 90 –0.04 l 0.03 1.46
11 D287 1,200 l 310a) 0.02 l 0.01 410 l 120 0.03 l 0.02 2.93
Steady-state GTPase activity in Sf9 membranes expressing hH1R and gpH1R in the presence of the RGS proteins 4 or 19 was deter-
mined as described in Experimental (section 3). Reaction mixtures contained HA (1 lM) and guanidines at concentrations from
1 nM to 100 lM as appropriate to generate saturated inhibition curves. Data were analyzed by non-linear regression and were best
fit to sigmoid concentration/response curves. Typical basal GTPase activities ranged between l1.5–2.5 pmol/mg/min, and the max-
imum stimulatory effect of histamine (100 lM) amounted to 125–175% above basal. The efficacy (Emax) of histamine was set 1.00.
The Emax values of other compounds (examined at a fixed concentration of 10 lM) were referred to this value. Data shown are the
means l SD of 5–8 experiments performed in duplicates each.
a) p a 0.05 for comparison of hH1R and gpH1R.
14 S.-X. Xie et al. Arch. Pharm. Chem. Life Sci. 2007, 340, 9 –16
achievement of the long-term goal, i.e. the availability of
highly potent and efficacious hH2R agonists, is difficult.
Probably, the most efficient strategy will be to perform
parallel molecular modeling, compound synthesis, and
site-directed mutagenesis studies to fully understand the
molecular mechanisms of agonist / H2R interactions. The
detailed analysis of other H2R species isoforms including
those of rat and dog [1, 2], will be very informative in this
respect, too. Moreover, there are a number of amino acid
differences between hH2R and gpH2R in the N-terminus,
the second intracellular loop, and the C-terminus which
could contribute to differences in agonist binding and/or
G-protein coupling [9]. Understanding the functional
relevance of these structural differences between recep-
tor isoforms will be important for future agonist synth-
esis as well.
ARP-derived guanidines but not IMP-derived guani-
dines are also moderately potent H1R antagonists (Tables
2 and 3). These data show that H1R readily accommodates
the second aromatic ring system present in ARP deriv-
atives and that interaction of the aromatic rings with
H1R contributes substantially to antagonist-affinity. In
terms of potential therapeutic application of ARP deriv-
atives for inflammatory diseases, H1R antagonism is actu-
ally an interesting property since H2R agonism and H1R
antagonism should result in at least additive anti-inflam-
matory effects [1, 2, 21]. The gpH2R shows a three- to five-
fold higher affinity for guanidines than hH2R (Table 1),
but for H1R species isoforms, the affinity difference varies
from 1.5- to 10-fold (Tables 2 and 3). These data show that
the specific aromatic ring systems and their substituents
have a much greater impact on H1R- than H2R-affinity.
Most notably, 10, bearing a phenyl- and a 3,4-dichloro-
phenyl group, exhibits very similar affinity at hH1R and
gpH1R, whereas 9, bearing two 4-fluorophenyl groups,
exhibits 10-fold preference for gpH1R compared to hH1R.
Thus, ARP-derived guanidines may become very valuable
tools to explore the antagonist binding site of H1R.
In this context, it should be noted that the antagonist
affinity ratios for the hH1R species isoforms in the
[3H]mepyramine competition binding assay and the
GTPase inhibition assay show some differences (Tables 2
and 3). For example, in the competition binding assay, 8
exhibits similar affinity at both receptor isoforms,
whereas in the GTPase inhibition assay, the affinity-dif-
ference is more than fourfold. A possible explanation for
these differences is that the two assays assess different
H1R populations with different ligand affinities, i. e. the
[3H]mepyramine-bound H1R (competition binding assays)
and the HA-bound H1R (GTPase inhibition assay). Thus,
guanidines may also become valuable tools to explore
multiple ligand-specific H1R conformations. The useful-
ness of guanidines for the exploration of ligand-specific
H2R conformations was already established in a previous
study [9].
A last aspect that needs to be discussed concerns the
constitutive, i. e. agonist-independent, activity of the H1R.
It is known that several H1R antagonists act as inverse
agonists as is reflected by a decrease in basal G-protein
activity [11, 23]. However, to this end, specific structure-
activity relationships for inverse agonistic activity have
remained largely unexplored. Our present study shows
that IMP derivatives 3, 4 lack inverse agonistic H1R activ-
ity, whereas certain ARP derivatives 6, 7, 9 clearly display
inverse agonism (Table 3). These data indicate that two
aromatic ring systems at the guanidino group are
required for inverse agonism. However, ARP derivatives
10 and 11 lacked inverse agonistic activity. An important
difference between the latter two ARP derivatives and the
former ARP derivatives is that 6, 7, and 9 bear a fluoro-
phenyl substituent, whereas 10 and 11 bear chlorophenyl
substituents. Thus, ARP-derived guanidines will also help
us elucidate the structural requirement for inverse agon-
ism at H1R and explore the possible physiological func-
tion of H1R constitutive activity.
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Experimental
Chemistry
Melting points (uncorrected) were determined with a Bchi 530
apparatus (Bchi, Flawil, Switzerland). 1H-NMR (250 MHz) were
recorded on a Bruker WM 250 NMR spectrometer (Bruker, Karls-
ruhe, Germany) (chemical shift d in ppm, relative to tetramethyl-
silane, J in Hz, s = singulett, d = doublet, t = triplett, m = multi-
plet, br = broad). Elemental analyses (C, H, N) were performed by
the Microanalytical Laboratory of the University of Regensburg.
+FAB mass spectra (methanol, glycerol, xenon) were recorded
using a FinniganMAT 95mass spectrometer (Bremen, Germany).
Thin-layer chromatography (TLC) was done on silica gel 60 F254
(Merck, Darmstadt, Germany) coated on aluminium sheets.
Chromatographic separations on a preparative scale were per-
formed with a Chromatotron, model 8924 (Harrison Research,
Palo Alto, CA, USA) on 2 or 4 mm layers of silica gel 60 PF254 con-
taining gypsum (Merck). The analytical HPLC system consisted of
a 655A-12 Liquid Chromatograph (Merck), a L-5000 LC controller
i 2007WILEY-VCH Verlag GmbH &Co. KGaA,Weinheim www.archpharm.com
Arch. Pharm. Chem. Life Sci. 2007, 340, 9 –16 Effects of Guanidines on H1- and H2 Receptors 15
(Merck), a L-4250 UV-VIS detector (Merck), a 655A-40 auto sam-
pler (Merck), a D2000 Chromo-Integrator (Merck), a LiChrosorb
RP18 (Merck) 7 lm column (250 mm64 mm) using mixtures of
MeOH and 0.1% aqueous trifluoroacetic acid (TFA) as eluent,
flow rate: 1 mL/min.
The guanidines 2–10were synthesized as described elsewhere
[4, 14–17], the compounds 11, 12were prepared by analogy with
known procedures as outlined below. The purity of the pharma-
cologically investigated compounds was F98% unless otherwise
indicated, as determined by high-performance liquid chromato-
graphy or capillary electrophoresis according to previously
describedmethods [24, 25].
N1-[3-(3,4-Dichlorophenyl)-3-(2-thiazolyl)propyl]-N2-[3-
(1H-imidazol-4-yl)propyl]guanidine 11 and N1-[3-(3,4,5-
trichlorophenyl)-3-(2-thiazolyl)propyl]-N2-[3-(1H-imidazol-
4-yl)propyl]guanidine 12
3-(3,4-Dichlorophenyl)-3-(2-thiazolyl)propylamine and 3-(3,4,5-
trichlorophenyl)-3-(2-thiazolyl)propylamine were prepared from
the corresponding aromatic ketones via condensation with
diethyl cyanomethanephosponate and stepwise reduction of the
double bond and the nitrile group; see procedure described in
[19]. The pertinent amine (2 mmol) and diphenoxymethylene-
carbamic acid t-butyl ester (626 mg, 2 mmol) were stirred in acet-
onitrile (10 mL) for 10 min. After addition of 3-(1H-imidazol-4-
yl)propylamine (250 mg, 2 mmol) the mixture was heated to
reflux for 3–5 h (control by TLC). The solution was evaporated in
vacuo, the residue was taken up in 20 mL of 5% acetic acid, phe-
nol was removed by extraction with diethyl ether, and after basi-
fication with aqueous ammonia the intermediate, the corre-
sponding guanidine-N-carboxylic acid t-butyl ester, was
extracted with methylene chloride and isolated chromatogra-
phically from the dried (Na2SO4) and evaporated organic layer
(Chromatotron, eluent: CHCl3 then CHCl3/MeOH 1 :1, NH3 atmo-
sphere).
1,1-Dimethylethyl {[3-(3,4-dichlorophenyl)-3-(2-
thiazolyl)propylamino][3-(1H-imidazol-4-
yl)propylamino]methylidene}carbamate
Yield 63%, m. p. 988C (product stirred with MeOH/hexane); +FAB-
MS: m/z (% rel. intensity) = 537 [MH+] (60), 437 [MH–Boc]+, (100).
Analysis C24H30Cl2N6O2S60.5 CH3OH (553.5). Anal. calcd.: C
53.16, H 5.83, N 15.18; found: C 53.06, H 5.86, N 14.96. HPLC:
retention time (tR) 28.34 min, eluting with MeOH/0.1% aqueous
TFA, 50 : 50.
1,1-Dimethylethyl {[3-(3,4,5-trichlorophenyl)-3-(2-
thiazolyl)propylamino][3-(1H-imidazol-4-
yl)propylamino]methylidene}carbamate
Yield 44%, m. p. 788C; +FAB-MS: m/z (% rel. intensity) = 571 [MH+]
(68), 471 [MH–Boc]+ (100), analysis C24H29Cl3N6O2S6CH3OH
(604.0). Anal. calcd.: C 49.71, H 5.51, N 13.91; found: C 49.66, H
5.17, N 13.69. HPLC: tR 5.10 and 15.83 min eluting with MeOH/
0.1% aqueous TFA, 70 :30 and 60 :40, respectively.
The Boc-protected intermediates were stirred with 5 mL of
1 M hydrochloric acid at 708C for 1 h, evaporated to dryness to
obtain the trihydrochlorides of 11 and 12 as hygroscopic solid 11
or dry foam 12.
11: Yield 95%; m. p. 1258C; analysis, C19H22Cl2N6S63HCl6
2H2O (582.8). Anal. calcd.: C 39.16, H 5.02, N 14.42; found: C
38.72, H 5.37, N 14.13. HPLC: tR 8.66 and 20.09 min eluting with
MeOH / 0.1% aqueous TFA, 50 :50 and 40 60, respectively. 1H-
NMR [D2O]: d (ppm) = 8.47 (1H, d, J = 1.5 Hz), 7.74 (1H, d, J = 3.7
Hz), 7.58 (1H, d, J = 3.6), 7.47 (1H, d, J = 2.2 Hz), 7.42 (1H, d, J = 8.3
Hz), 7.20 (1H, dd, J = 8.3 Hz, J = 2.2 Hz), 7.10 (1H, d, J = 1.0 Hz),
4.59–4.50 (1H, m), 3.25-3.13 (2H, m), 2.93 (2H, t, J = 7.2 Hz), 2.59
(2H, t, J = 7.5 Hz), 2.49-2.37 (2H, m), 1.71 (2H, tt, J = 7.5 Hz, J = 7.2
Hz). +FAB-MS: m/z (% rel. intensity) = 437 [MH+] (100).
12: Yield 93%, hygroscopic foam, C19H21Cl3N6S6 3HCl (581.2).
Purity A95%, determined by HPLC: tR 16.57 min, eluent MeOH/
0.1% aqueous TFA, 50 : 50. 1H-NMR: d (ppm) = 8.47 (1H, d, J = 1.39
Hz), 7.69 (1H, d, J = 3.5 Hz), 7.51 (1H, d, J = 3.5 Hz), 7.42 (2H, s),
7.10 (1H, d, J = 1.0 Hz), 4.53–4.43 (1H, m), 3.20–3.11 (2H, m), 2.92
(2H, t, J = 7.1 Hz), 2.59 (2H, t, J = 7.7 Hz), 2.49-2.33 (2H, m), 1.70
(2H, tt, J = 7.7 Hz, J = 7.1 Hz). +FAB-MS: m/z (% rel. intensity) = 471
[MH+] (100).
Pharmacology
Construction of baculoviruses encoding hH2R-GsaS, gpH2R-GsaS,
hH1R, and gpH1R was described previously [9]. Baculoviruses
encoding RGS proteins 4 and 19 were a gift from Dr. E. Ross
(Department of Pharmacology, University of Southwestern Med-
ical Center, Dallas, TX, USA). Sources of other materials are
described elsewhere [9, 13]. Baculovirus infection and culture of
Sf9 cells and membrane preparation were performed as
described [9]. H2R-Gsa expression levels were 5–6 pmol/mg as
assessed by immunoblotting using the M1monoclonal antibody
and b2-adrenoceptor expressed at defined levels as standard [9].
H1R expression levels were 4–6 pmol/mg as assessed by
[3H]mepyramine saturation binding [11].
Steady-state GTPase activity assay
GTP hydrolysis in Sf9 membranes expressing H2R-Gsa fusion pro-
teins or H1R isoforms plus RGS proteins was determined as
described previously [9, 11]. In brief, assay tubes (100 lL) con-
tained Sf9 membranes (10 lg of protein/tube), various ligands,
1.0 mM MgCl2, 0.1 mM EDTA, 0.1 mM ATP, 100 nM GTP, 1 mM
adenylyl imidodiphosphate, 5 mM creatine phosphate, 40 lg
creatine kinase, and 0.2% (w/v) bovine serum albumin (BSA) in
50 mM Tris/HCl, pH 7.4, and [c– 32P]GTP (0.2–0.5 lCi/tube). Reac-
tions were conducted for 20 min at 258C and terminated by the
addition of 900 lL slurry consisting of 5% (w/v) activated char-
coal and 50 mM NaH2PO4, pH 2.0. 32Pi in supernatant fluids of
reaction mixtures was determined by liquid scintillation count-
ing.
Radioligand binding assay
[3H]Mepyramine competition binding experiments with Sf9
membranes expressing hH1R or gpH1R plus RGS proteins were
performed as described previously [11]. In brief, assay tubes
(500 lL) contained membranes (20–25 lg of protein/tube), 2 nM
[3H]mepyramine and unlabeled ligands in binding buffer
(12.5 mM MgCl2, 1 mM EDTA and 75 mM Tris/HCl, pH 7.4).
Bound radioligand was separated from free radioligand by filtra-
tion through GF/C filters, and filter-bound radioactivity was
determined by liquid scintillation counting.
Miscellaneous
Protein concentrations were determined using the Bio-Rad DC
protein assay kit (Bio-Rad, Hercules, CA, USA). All analyses of
experimental data were performed with the Prism 4.02 software
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(GraphPad-Prism, San Diego, CA, USA). Ki and KB values were cal-
culated using the Cheng and Prusoff equation [26]. Statistical
comparisons were performedwith the t-test.
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